Nadixa (Nadifloxacin)

Nadifloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. Inhibiting these targets stops bacterial cell division, leading to a bactericidal effect that eliminates susceptible skin pathogens and reduces inflammation associated with infection.

The dosage of Nadixa is determined by the prescribing clinician based on the severity of the skin condition, the area to be treated, and patient factors. The prescriber will specify the amount to apply, frequency, and duration of therapy on the product label or prescription.

Safety data for nadifloxacin in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy unless the potential benefit justifies the risk, and breastfeeding mothers should consult their healthcare provider before using the product.

To request Nadixa, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Nadixa (nadifloxacin) is a topical fluoroquinolone, whereas many alternative acne treatments belong to the macrolide or clindamycin classes. Fluoroquinolones have a broad spectrum against Gram‑positive and Gram‑negative bacteria and a low risk of resistance when used short‑term, but they may carry a higher potential for photosensitivity compared with macrolides.

Nadixa should be stored at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and ensure it is out of reach of children.

Nadixa is applied topically to the affected skin area. The prescriber will advise the amount to use, typically a thin layer, and the frequency—often once or twice daily. Hands should be washed before and after application, and the treated area should be clean and dry.

Serious risks, though rare, include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, toxic epidermal necrolysis, and photosensitivity leading to severe sunburn. Patients should discontinue use and seek immediate medical attention if they experience widespread rash, blistering, swelling, or breathing difficulties.

Nadixa should not be used by individuals with a known hypersensitivity to nadifloxacin or any fluoroquinolone, on extensive open wounds, burns, or mucous membranes, and it is contraindicated in patients where the prescriber determines the risks outweigh the benefits, such as certain pregnant or lactating women.